|
| Elizabeth Mallon | Dana-Farber Cancer Institute Richard D. Gelber and Meredith M. Regan, Harvard Medical School Karen N. Price, Southern General Hospital Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, European Institute of Oncology and University of Milan Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, and Swiss Group for Clinical Cancer Research, Rigshospitalet, Institut Bergoniie, and University of Sydney |
| Eric P Winer | Dana-Farber Cancer Institute Richard D. Gelber and Meredith M. Regan, Harvard Medical School Karen N. Price, Southern General Hospital Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, European Institute of Oncology and University of Milan Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, and Swiss Group for Clinical Cancer Research, Rigshospitalet, Institut Bergoniie, and University of Sydney |
| Meredith M Regan | Dana-Farber Cancer Institute Richard D. Gelber and Meredith M. Regan, Harvard Medical School Karen N. Price, Southern General Hospital Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, European Institute of Oncology and University of Milan Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, and Swiss Group for Clinical Cancer Research, Rigshospitalet, Institut Bergoniie, and University of Sydney |